Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

• Time to progression [ Time Frame: Every 6 weeks during treatment and after 6 cycle treatment every 18 weeks till progression ] [ Designated as safety issue: No ]
• Objective response rate [ Time Frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression ] [ Designated as safety issue: No ]
• Disease control rate [ Time Frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression ] [ Designated as safety issue: No ]
• Overall survival [ Time Frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression ] [ Designated as safety issue: No ]
• Trough concentration of Regorafenib and metabolites (for Europe only) [ Time Frame: Cycle 1 Day 15 and Cycle 2 Day 1 ] [ Designated as safety issue: No ]
• Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only) [ Time Frame: Cycle 1 Day 21 to Day 28 ] [ Designated as safety issue: No ]

• Time to progression [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
• Objective response rate [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
• Disease control rate [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
• Overall survival [ Time Frame: Every 6 weeks during treatment ] [ Designated as safety issue: No ]
• Trough concentration of Regorafenib and metabolites [ Time Frame: Cycle 1 and 2 ] [ Designated as safety issue: No ]

The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.

Inclusion Criteria:

• Male or female patients aged equal or above 18 years.
• BCLC stage Category A, B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, liver transplantation, local ablation, chemoembolization or systemic sorafenib.
• Liver function status Child-Pugh class A.
• Failure to prior treatment with sorafenib (defined as radiological progression under sorafenib therapy)
• Local or loco-regional therapy (eg, surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed = 4 weeks before first dose of BAY73-4506.
• ECOG PS of 0 or 1.
• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• Prior systemic treatment with molecular targeted agents for HCC, except sorafenib. Prior chemotherapy treatment is allowed.
• Known history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease).
• Congestive heart failure NYHA>/= class 2
• Unstable angina (angina symptoms at rest, new onset angina within the last 3 months) or myocardial infarction (MI) within the past 6 months before start of study medication.
• Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
• Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
• Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment.